[Ip-health] The List of Excluded Middle-Income Countries

Priti Radhakrishnan priti at i-mak.org
Mon Sep 15 06:17:03 PDT 2014

Here is the list of excluded middle-income countries:

On Mon, Sep 15, 2014 at 8:38 AM, Priti Radhakrishnan <priti at i-mak.org>

> I-MAK has analyzed the cost implications of the licenses announced today
> by Gilead Sciences on the Hepatitis C drug sofosbuvir. The 3 page report is
> available here: *http://tinyurl.com/mq35xdl <http://tinyurl.com/mq35xdl>*
> Gilead is reportedly excluding 51 middle-income countries (MICs) from its
> license for sofosbuvir, an oral hepatitis C drug. Across these MICs
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn2>, where nearly
> 50 million people are infected with hepatitis C virus (HCV), lack of access
> to generic sofosbuvir will increase the total cost of curing hepatitis C by
> an estimated *$60 billion dollars, *according to I-MAK’s analysis.
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn4>
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn4>
> I-MAK’s team based this estimate on generic price projections for
> sofosbuvir (~$135-400 per 12-week course of treatment), and the assumption
> that Gilead’s MIC price would be ~75% more than the $900 price they are
> expected to charge to low-income countries.
> <https://mail.google.com/mail/u/0/#148771184ad8acd4__ftn5> Even if Gilead
> were to extend its $900 access price to all middle-income countries – which
> is unlikely – these countries would still need to spend ~$30 billion more
> to treat their HCV patients than if generic versions of sofosbuvir were
> available. This underscores the need to address patent barriers for
> sofosbuvir to make HCV treatment affordable for these middle-income
> countries.
> We emphasize that the middle-income country price we used of $1,567 for
> sofosbuvir (with the 75% price premium) is a low-end estimate, and reports
> indicate that excluded countries have been quoted a much higher price (e.g.
> $7,000 for sofosbuvir). Therefore, the $60 billion estimate is likely to be
> very conservative indeed.
> Leaving large populations untreated instead of curing them will allow the
> epidemic to keep spreading. To meaningfully contribute to the solution,
> Gilead Sciences will need to reduce its price of sofosbuvir and promote
> robust generic competition in the 51 middle-income countries it has
> excluded from the license.
> --
> *Priti Radhakrishnan*
> Co-Founder and Director of Treatment Access, I-MAK
> Echoing Green Fellow | Pop!Tech Fellow | Asia Society Associate Fellow
> *"Where innovation meets access to affordable medicines"*
> *Website: *www.i-mak.org
> *Skype:* pritiwho
> *Mobile:* +1 917 703 2876
> *E-mail:* priti at i-mak.org

More information about the Ip-health mailing list